Literature DB >> 15304026

Use of different D-dimer levels to exclude venous thromboembolism depending on clinical pretest probability.

L A Linkins1, S M Bates, J S Ginsberg, C Kearon.   

Abstract

Currently, the same D-dimer cut-off point is used to define a positive result for all patients with suspected venous thromboembolism, regardless of their pretest probability. However, use of a relatively high D-dimer cut-off point (lower sensitivity) for those with a low clinical pretest probability, and a low D-dimer cut-off point (higher sensitivity) for those with a high clinical pretest probability, may be preferable. To determine if using three different D-dimer cut-off points according to low, moderate or high clinical pretest probability has greater utility for exclusion of venous thromboembolism than using the same single D-dimer cut-off point in all patients. Data from a previously published study of 571 patients was used to identify the highest D-dimer cut-off point with a negative predictive value of at least 98% for the subgroup of patients with low and high pretest probability. The D-dimer cut-off point for those with moderate clinical pretest probability remained unchanged [0.5 fibrinogen equivalent units (FEU) microgram mL(-1)]. Accuracy of D-dimer testing for venous thromboembolism using three cut-off points vs. one cut-off point was than determined. D-dimer cut-off points of 0.2 and 2.1 FEU microgram mL(-1) were selected for the high and low pretest probability groups, respectively. When three pretest probability-specific cut-off points were used instead of the previously determined single D-dimer cut-off point (0.5 FEU microgram mL(-1)), sensitivity and negative predictive value were unchanged (95 and 98%, respectively), but specificity increased from 44.7 to 60.4% (P < 0.001). This resulted in exclusion of venous thromboembolism in 80 additional patients. Use of three pretest probability-specific D-dimer cut-off points rather than a single D-dimer cut-off point for all patients, has the potential to increase the utility of D-dimer testing for the diagnosis of venous thromboembolism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304026     DOI: 10.1111/j.1538-7836.2004.00824.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  12 in total

1.  Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux.

Authors:  Kakunoshin Yoshida; Hideo Wada; Masahiro Hasegawa; Hiroki Wakabayashi; Takeshi Matsumoto; Yuji Shimokariya; Katsura Noma; Norikazu Yamada; Atsumasa Uchida; Tsutomu Nobori; Akihiro Sudo
Journal:  Int J Hematol       Date:  2012-01-21       Impact factor: 2.490

2.  D-dimer threshold increase with pretest probability unlikely for pulmonary embolism to decrease unnecessary computerized tomographic pulmonary angiography.

Authors:  J A Kline; M M Hogg; D M Courtney; C D Miller; A E Jones; H A Smithline
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

3.  Negative predictive value of D-dimer for diagnosis of venous thromboembolism.

Authors:  Hideki Nomura; Hideo Wada; Toshiro Mizuno; Naoyuki Katayama; Yasunori Abe; Maki Noda; Kaname Nakatani; Takeshi Matsumoto; Satoshi Ota; Norikazu Yamada; Akihiro Sudo; Atsumasa Uchida; Tsutomu Nobori
Journal:  Int J Hematol       Date:  2008-02-19       Impact factor: 2.490

4.  Cut-off values of D-dimer and soluble fibrin for prediction of deep vein thrombosis after orthopaedic surgery.

Authors:  Akihiro Sudo; Hideo Wada; Tsutomu Nobori; Norikazu Yamada; Masaaki Ito; Rui Niimi; Masahiro Hasegawa; Koji Suzuki; Atsumasa Uchida
Journal:  Int J Hematol       Date:  2009-05-09       Impact factor: 2.490

5.  Significance of plasma D-dimer in relation to the severity of atherosclerosis among patients evaluated by non-invasive indices of cardio-ankle vascular index and carotid intima-media thickness.

Authors:  Shigeru Hayashi
Journal:  Int J Hematol       Date:  2010-06-18       Impact factor: 2.490

6.  Elevated levels of soluble fibrin in patients with venous thromboembolism.

Authors:  Akihiro Tsuji; Hideo Wada; Takeshi Matsumoto; Yasunori Abe; Satoshi Ota; Norikazu Yamada; Takashi Sugiyama; Akihiro Sudo; Katsuya Onishi; Kaname Nakatani; Atsumasa Uchida; Masaaki Ito; Koji Suzuki; Tsutomu Nobori
Journal:  Int J Hematol       Date:  2008-10-04       Impact factor: 2.490

7.  Proximal and isolated distal deep vein thrombosis and Wells score accuracy in hospitalized patients.

Authors:  Marcello Di Nisio; Emanuele Valeriani; Ettore Porreca
Journal:  Intern Emerg Med       Date:  2019-05-09       Impact factor: 3.397

8.  Current status of venous thromboembolism development during the perioperative period for colorectal cancer, its prevention with enoxaparin, and monitoring methods.

Authors:  Jun Aoki; Kazuhiro Sakamoto; Rina Takahashi; Koichiro Niwa; Shun Ishiyama; Kiichi Sugimoto; Hirohiko Kamiyama; Makoto Takahashi; Yutaka Kojima; Michitoshi Goto; Yuichi Tomiki; Toshiaki Iba
Journal:  Ther Clin Risk Manag       Date:  2019-06-21       Impact factor: 2.423

9.  Expression of vascular infarction-related molecules after anti-vascular endothelium growth factor treatment for diabetic macular edema.

Authors:  Masahiko Sugimoto; Yasuko Wakamatsu; Ryohei Miyata; Takayasu Nunome; Yumiho Tenma; Hisashi Matsubara; Mineo Kondo; Hideo Wada; Kaname Nakatani
Journal:  Sci Rep       Date:  2019-08-26       Impact factor: 4.379

10.  Economic evaluation of different screening alternatives for patients with clinically suspected acute deep vein thrombosis.

Authors:  Natasa Bogavac-Stanojević; Violeta Dopsaj; Zorana Jelić-Ivanović; Dragana Lakić; Dragan Vasić; Guenka Petrova
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.